GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alzinova ALZ.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.33

-3.92%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alzinova

Its shares trade on Nasdaq Stockholm under the ticker ALZ.ST. It has been listed since 25 November 2015. In the fiscal year to 31 December 2025, it reported a net loss of SEK 26.3m. At that date it held total assets of SEK 143.4m and shareholders' equity of SEK 122.0m.

Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2015-11-25. The firm is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The firm focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Nov 2015

Leadership

Pay as last reported

  • Mr. Julian AleksovChairman of the Board, since 2023
  • Dr. Tord LabudaChief Executive Officer
  • Mr. Erik KullgrenChief Financial Officer
  • Mr. Anders SandbergChief Scientific Officer, since 2015
  • Mr. Andreas BlomDirector, since 2016
  • Mr. Anders WaasDirector
  • Dr. Per-Goran GillbergIndependent Director
  • Mr. Clas MalmestromIndependent Director, since 2015
  • Dr. Carol RoutledgeIndependent Director, since 2018

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Alzinova AB focuses on the discovery of therapeutics for Alzheimer's disease treatment.
  • The firm develops the specific oligomer-directed vaccine ALZ-101 for brain synapse protection.
  • ALZ-201 diagnostics are based on a monoclonal antibody targeting oligomeric Aβ.

Weaknesses

  • The company is headquartered in Moelndal, Vastra Gotalands, Sweden.
  • Alzinova AB went public on 25 November 2015 via an IPO.
  • The firm operates within the Health Care sector in Sweden.

Opportunities

  • Alzinova AB engages in research and development of drugs for Alzheimer's.
  • The firm focuses on development of diagnostics based on ALZ-201.
  • Both products target the form of oligomeric Aβ damaging brain synapses.

Threats

  • Alzinova AB operates in the Biotechnology industry within the Health Care sector.
  • The company is listed on the stock exchange since 2015.
  • Moelndal is the city where the firm is headquartered in Sweden.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.